Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 1, 2010, Pages 54-61

  Lekander, Ingrid ^a   Borgstrm, Fredrik ^a   Svarvar, Patrick ^a   Ljung, Tryggve ^a   Carli, Cheryl ^b   Van Vollenhoven, Ronald F ^b  

^a LIME ^*  (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Clinical practice; Markov model; RA; Registry data

Indexed keywords

BIOLOGIC TREATMENT; BIOLOGICAL TREATMENT; CLINICAL PRACTICES; DISEASE PROGRESSION; HEALTH ASSESSMENTS; INCREMENTAL COST; INPUT PARAMETER; MARKOV MODEL; MODEL ASSUMPTIONS; MORTALITY RATE; QUALITY-ADJUSTED LIFE YEARS; REAL-WORLD; RHEUMATOID ARTHRITIS; SOCIETAL COSTS; STOCKHOLM; TRANSITION PROBABILITIES; VALUE FOR MONIES;

BIOCHEMICAL ENGINEERING; COST EFFECTIVENESS; COSTS; HEALTH; MARKOV PROCESSES; SENSITIVITY ANALYSIS;

COST BENEFIT ANALYSIS;

INFLIXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HIDDEN MARKOV MODEL; MORTALITY; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SIMULATION; SWEDEN; AGE DISTRIBUTION; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; HUMAN; PROBABILITY; REGISTER; SEX RATIO; STATISTICS;

AGE DISTRIBUTION; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; SEX DISTRIBUTION; SWEDEN;

EID: 77949899273     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990596     Document Type: Article

References (27)

1. Askling J. Risk for tuberculosis following treatment of rheumatoid arthritis with anti-TNF therapy-the Swedish experience 1998-2008. Ann Rheum Dis. 2009;68(Suppl 3):422.
2. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986-1992.
3. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:1339-1344.
4. Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford). 2007;46:1345-1354.
5. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford). 2004;43:62-72.
6. Chehata JC, Hassell AB, Clarke SA, et al.Mortality in rheumatoid arthritis: Relationship to single and composite measures of disease activity. Rheumatology (Oxford). 2001;40:447-452.
7. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10:1-248.
8. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12:555-569.
9. Ekman M, Zethraeus N, Dahlstrom U, Hoglund C. [Costeffectiveness of bisoprolol in chronic heart failure]. Lakartidningen. 2002;99:646-650.
10. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61:793-798.
11. Jacobsson LTH, Lindroth Y,Marsal L, Bergström U, Kobelt G. Rheumatoid arthritis: What does it cost and what factors are driving those costs? Results of a survey in a communityderived population in Malmö, Sweden. Scand J Rheumatol. 2007;36:179-183.
12. Katz PP. The impact of rheumatoid arthritis on life activities. Arthritis Care Res. 1995;8:272-278.
13. Kobelt G, Jonsson L, Young A, Eberhardt K. The costeffectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on theATTRACT study. Rheumatology (Oxford). 2003;42:326-335.
14. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford). 2005;44:1169-1175.
15. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005;64:1174-1179.
16. Kroot EJ, van Leeuwen MA, van Rijswijk MH, et al. No increased mortality in patients with rheumatoid arthritis: Up to 10 years of follow up from disease onset. Ann Rheum Dis. 2000;59:954-958.
17. Leden IRS. Rapport fr°an v°ardprocess: Reumatologi dyr läkemedelsbehandling. 2003.
18. LFN Kostnadseffektiva läkemedel-LFN. http://www.tlv.se/ upload/Bakgrundsmaterial/kostnadseffektiva - lakemedel. pdf (accessed September 25, 2008)
19. Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis. 1999;58:11-14. (Pubitemid 29112944)
20. Meltzer D. Accounting for future costs in medical costeffectiveness analysis. J Health Econ. 1997;16:33-64.
21. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-872.
22. Riise T, Jacobsen BK,Gran JT, HagaHJ, Arnesen E. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol. 2001;20:123-127.
23. Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford). 2000;39:122-132.
24. Silman A, Hochberg M. Epidemiology of rheumatic diseases. 1993. Oxford: Oxford University Press.
25. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. J Rheumatol. 1998;25:1072-1077.
26. Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol. 2002;29:1851-1857.
27. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 2002;61:335-340.